1. Home
  2. FSK vs SUPN Comparison

FSK vs SUPN Comparison

Compare FSK & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

FSK

FS KKR Capital Corp.

HOLD

Current Price

$10.51

Market Cap

2.8B

Sector

Finance

ML Signal

HOLD

Logo Supernus Pharmaceuticals Inc.

SUPN

Supernus Pharmaceuticals Inc.

HOLD

Current Price

$49.57

Market Cap

3.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FSK
SUPN
Founded
2007
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.8B
3.0B
IPO Year
2008
2010

Fundamental Metrics

Financial Performance
Metric
FSK
SUPN
Price
$10.51
$49.57
Analyst Decision
Hold
Strong Buy
Analyst Count
8
5
Target Price
$13.19
$61.60
AVG Volume (30 Days)
3.2M
412.5K
Earning Date
05-06-2026
05-05-2026
Dividend Yield
19.00%
N/A
EPS Growth
N/A
N/A
EPS
0.04
N/A
Revenue
N/A
$392,755,000.00
Revenue This Year
N/A
$22.70
Revenue Next Year
N/A
$19.14
P/E Ratio
$265.25
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.72
$29.16
52 Week High
$22.68
$59.68

Technical Indicators

Market Signals
Indicator
FSK
SUPN
Relative Strength Index (RSI) 45.13 45.58
Support Level $9.85 $49.46
Resistance Level $10.56 $52.26
Average True Range (ATR) 0.35 1.60
MACD 0.07 -0.03
Stochastic Oscillator 35.82 30.39

Price Performance

Historical Comparison
FSK
SUPN

About FSK FS KKR Capital Corp.

FS KKR Capital Corp is an externally managed, non-diversified, closed-end management investment company that has elected to be regulated as a business development company. The company's investment objectives are to generate current income and, to a lesser extent, long-term capital appreciation. The company's portfolio is comprised of investments in senior secured loans and second lien secured loans of private middle market U.S. companies and, to a lesser extent, subordinated loans and certain asset-based financing loans of private U.S. companies.

About SUPN Supernus Pharmaceuticals Inc.

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.

Share on Social Networks: